New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
10:53 EDTFLXNFlexion IPO opens at $16.00, IPO priced at $13.00
Flexion (FLXN) priced 5M shares at $13.00. BMO Capital and Wells Fargo acted as joint book running managers for the offering.
News For FLXN From The Last 14 Days
Check below for free stories on FLXN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
09:07 EDTFLXNFlexion trial likely to be allowed to continue, says Summer Street
Subscribe for More Information
06:19 EDTFLXNFlexion to host conference call
Conference call to discuss clinical hold of FX006 phase 2b clinical trial in Osteoarthritis of the knee will be held on September 18 at 9 am. Webcast Link
September 17, 2014
18:29 EDTFLXNOn The Fly: After Hours Movers
Subscribe for More Information
16:10 EDTFLXNFlexion drops 18% to $15.83 after FDA places clinical hold on study
Subscribe for More Information
16:08 EDTFLXNFlexion announces clinical hold on Phase 2b trial enrollment
Flexion Therapeutics announced that the FDA informed the company yesterday that a clinical hold has been placed on patient enrollment and dosing in an ongoing Phase 2b clinical trial evaluating FX006 in patients with osteoarthritis of the knee. FX006 is a novel, non-opioid, sustained-release, intra-articular formulation of triamcinolone acetonide targeting moderate-to-severe OA pain. Flexion said it has not yet received written notice of its clinical hold from the FDA, but based on the verbal communication yesterday afternoon, the FDA indicated that the clinical hold is due to a single occurrence of an infection in the injected knee joint of a patient in the Phase 2b clinical trial.
September 9, 2014
16:12 EDTFLXNFlexion issued composition of matter patent for lead candidate FX006
Flexion Therapeutics announced that the U.S. Patent and Trademark Office has issued a composition of matter patent, entitled "Corticosteroids for the Treatment of Joint Pain," which provides coverage for FX006, the company's lead clinical product candidate. FX006 is a novel, non-opioid, sustained-release, intra-articular formulation of triamcinolone acetonide.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use